A Phase 1b Study of AMG 757 in Subjects with Neuroendocrine Prostate Cancer

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513316-10-00

Acronym

20200040

Enrollment

Registered

2024-08-02

Start date

2021-04-20

Completion date

2024-06-07

Last updated

2024-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult subjects with de novo or treatment-emergent neuroendocrine prostate cancer

None listed

Sex/Gender

Male

Age

18 Years to No maximum

Belgium, France, Netherlands

None listed

Source: EU CTIS · Data processed: Feb 4, 2026